- Pfizer has begun phase 1 testing of an mRNA flu vaccine.
- The big drugmaker is nearly three months behind Moderna, which began testing its flu vaccine in July.
- mRNA vaccines could potentially target more flu strains with one dose than other flu vaccines.
Pfizer (NYSE:PFE) continues to rake in billions of dollars in sales for its messenger RNA (mRNA) COVID-19 vaccine developed with BioNTech (NASDAQ:BNTX). However, the big drugmaker has bigger plans for its mRNA vaccine program. In this Motley Fool Live video recorded on Sept. 29, Motley Fool contributors Keith Speights and Brian Orelli discuss Pfizer's next mRNA vaccine candidate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.